Skip to Main Content

Author Details

Nuala McCabe
Queen's University Belfast
2001
26
18
PMIDPaper TitleJournal TitlePublished Year
33396656ATM Kinase Inhibition Preferentially Sensitises PTEN-Deficient Prostate Tumour Cells to Ionising Radiation.Cancers (Basel)2020
31874245miR-191 promotes radiation resistance of prostate cancer through interaction with RXRA.Cancer Lett2020
31346333A Novel Role for Cathepsin S as a Potential Biomarker in Triple Negative Breast Cancer.J Oncol2019
31493898Defining the molecular evolution of extrauterine high grade serous carcinoma.Gynecol Oncol2019
31320901DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.J Oncol2019
29540831FES-related tyrosine kinase activates the insulin-like growth factor-1 receptor at sites of cell adhesion.Oncogene2018
29435137Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.Oncotarget2017
27014722The role of PTEN as a cancer biomarker.Oncoscience2016
27707838Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.J Natl Cancer Inst2016
27472395IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin.Oncotarget2016
27353327Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line.Nucleic Acids Res2016
25870146Mechanistic Rationale to Target PTEN-Deficient Tumor Cells with Inhibitors of the DNA Damage Response Kinase ATM.Cancer Res2015
27308567When the guardian becomes the enemy: Targeting ATM in PTEN-deficient cancers.Mol Cell Oncol2015
22939387Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.Eur Urol2013
20227038DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.Cancer Cell2010
19182824Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer.Oncogene2009
16912188Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.Cancer Res2006
15829967Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.Nature2005
16869747Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer.Cold Spring Harb Symp Quant Biol2005
16251802BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.Cancer Biol Ther2005
15205325BRCA1 interacts with and is required for paclitaxel-induced activation of mitogen-activated protein kinase kinase kinase 3.Cancer Res2004
12546697Role played by BRCA1 in regulating the cellular response to stress.Biochem Soc Trans2003
12546807X-chromosome inactivation: X marks the spot for BRCA1.Curr Biol2003
12011077BRCA1 regulates the interferon gamma-mediated apoptotic response.J Biol Chem2002
11593420BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.Oncogene2001
11709053Uncovering BRCA1-regulated signalling pathways by microarray-based expression profiling.Biochem Soc Trans2001
  • 1 - 26 of 26

Recommended Authors

Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 1
Patrick C O'Leary
University of California San Francisco
Career Start Year 2010
Number of shared co-authors 1
Jordi Carreras Puigvert
Department of Pharmaceutical Biosciences, Uppsala University
Career Start Year 2009
Number of shared co-authors 0
Georgia Velimezi
University of Patras
Career Start Year 2008
Number of shared co-authors 1
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 0
David W Cescon
Princess Margaret Cancer Centre
Career Start Year 2003
Number of shared co-authors 1
Justin Cidado
Oncology R&D
Career Start Year 2003
Number of shared co-authors 0
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 0
Darran P O'Connor
UCD Conway Institute, University College Dublin
Career Start Year 2001
Number of shared co-authors 0
Junjie Chen
The University of Texas MD Anderson Cancer Center
Career Start Year 2000
Number of shared co-authors 1
Euan A Stronach
Imperial College London
Career Start Year 1999
Number of shared co-authors 2
Eddy S Yang
University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Career Start Year 1999
Number of shared co-authors 0
Thomas Helleday
The University of Sheffield
Career Start Year 1998
Number of shared co-authors 2
Yaoqi Alan Wang
The University of Texas MD Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 0
Shiaw-Yih Lin
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 0
Christopher J Bakkenist
UPMC Hillman Cancer Center, University of Pittsburgh
Career Start Year 1994
Number of shared co-authors 0
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 2
Simon N Powell
Memorial Sloan Kettering Cancer Center
Career Start Year 1990
Number of shared co-authors 1
Ben Ho Park
Vanderbilt University Medical Center
Career Start Year 1990
Number of shared co-authors 0
Robert G Bristow
University of Toronto
Career Start Year 1989
Number of shared co-authors 9
James M Ford
Stanford University
Career Start Year 1989
Number of shared co-authors 1
Jos Jonkers
Oncode Institute, Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 3
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 1
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 2
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 0
Alvaro N A Monteiro
H. Lee Moffitt Cancer Center & Research Institute
Career Start Year 1985
Number of shared co-authors 4
Ashok R Venkitaraman
University of Cambridge, Hutchison Research Centre
Career Start Year 1982
Number of shared co-authors 1
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 1
Scott H Kaufmann
Mayo Clinic
Career Start Year 1977
Number of shared co-authors 1
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 4

Collaborators

Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Co-authored papers 7
Stephen P Jackson
Mission Therapeutics Ltd. Glenn Berge Building
Co-authored papers 2
Darragh G McArt
Queen's University Belfast
Co-authored papers 2
Edison T Liu
USA The Jackson Laboratory Cancer Center
Co-authored papers 2
Lara Dura-Perez
Queen's University Belfast
Co-authored papers 1
Michelle R Downes
University of Toronto
Co-authored papers 1
Ian G Mills
Queen's University Belfast
Co-authored papers 1
Jouhyun Jeon
Ontario Institute for Cancer Research
Co-authored papers 1
Clark Chen
University of Minnesota
Co-authored papers 1
Christianne Hoey
Evaluative Clinical Sciences, Sunnybrook Research Institute
Co-authored papers 1
Ronny Drapkin
University of Pennsylvania School of Medicine
Co-authored papers 1
Suneil Jain
Cancer Centre Belfast City Hospital, Queen's University Belfast
Co-authored papers 1
Stanley K Liu
Odette Cancer Centre, University of Toronto
Co-authored papers 1
Timothy S Davison
Co-authored papers 1
Ross Murphy
Queen's University Belfast
Co-authored papers 1
Paul C Boutros
University of California los angeles
Co-authored papers 1
Charles Haughey
Queen's University Belfast
Co-authored papers 1
Jessica Ray
Sunnybrook Research Institute, University of Toronto
Co-authored papers 1
Iain A McNeish
Ovarian Cancer Action Research Centre, Imperial College London
Co-authored papers 1
Release 1.2